Top Breaking News | More News | Featured Stories | News By Subject | Event News | Investor News | News Archive | Search News
Get Our FREE
Industry eNewsletter

Investor News

Clinical Development News
Phase I - Safety
Phase II - Safety and Efficacy
Phase III - Controlled Safety and Efficacy
Approvable Letters
Approval and Marketing Clearance
Recalls and Warnings

Deals & Dollars News
Earnings Reports
Mergers and Acquisitions

IPO News

Clinical - Phase II
Flexion Therapeutics (FLXN) CEO Discusses Pipeline and Jobs 3/13/2015 2:38:07 PM
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015 3:00:08 PM
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Meets Key Efficacy Objectives In Phase II Clinical Trial In Patients With Severe Dry Eye Reported In Current Issue Of Cornea 4/1/2015 7:00:43 AM
Kala Pharmaceuticals KPI-121 Meets Primary Sign Endpoint In Phase II For Dry Eye Disease 4/1/2015 11:40:10 AM
Burzynski Research Institute Announces Publication Of Phase II Results In Adults With Newly-Diagnosed Anaplastic Astrocytoma 4/1/2015 12:35:30 PM
Anergis Announces Completion Of Treatment In AllerT Phase II Dose-Ranging Trial 4/1/2015 9:27:07 AM
Hutchison Medipharma's Cancer Drug Meets Endpoint In Phase II Trial 4/1/2015 8:49:45 AM
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015 8:31:26 AM
NIH Funds Study Of Fully Personalized Immunotherapy AGS-004 Combined With A Latency Reversing Therapy For The Treatment Of HIV 4/1/2015 7:14:31 AM
Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy 4/1/2015 6:39:56 AM
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015 6:32:10 AM
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015 6:10:40 AM
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015 6:01:20 AM
RedHill Biopharma Ltd. (RDHL) Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech 3/31/2015 7:12:22 AM
Ocata Therapeutics Successfully Completes Dosing In Phase 1/2 RPE Studies 3/31/2015 11:18:38 AM